Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 155-163

  Gomes, Felipe V ^a   Llorente, Ricardo ^b   Del Bel, Elaine A ^a   Viveros, Maria Paz ^b   López Gallardo, Meritxell ^b   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Astrocytes; Cannabinoid; Clozapine; Microglia; MK 801; NeuN; NMDA receptor; Psychosis

Indexed keywords

CANNABIDIOL; CLOZAPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; AMINO ACID RECEPTOR BLOCKING AGENT; CALCIUM BINDING PROTEIN; DIZOCILPINE MALEATE; ENOLASE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CORPUS STRIATUM; DORSAL HIPPOCAMPUS; GLIA; MALE; MEDIAL PREFRONTAL CORTEX; MICROGLIA; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; NUCLEUS ACCUMBENS CORE; NUCLEUS ACCUMBENS SHELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; MAZE TEST; METABOLISM; PATHOLOGY; PSYCHOTIC DISORDERS; RECOGNITION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CALCIUM-BINDING PROTEINS; CANNABIDIOL; CLOZAPINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; NEUROGLIA; PHOSPHOPYRUVATE HYDRATASE; PSYCHOTIC DISORDERS; RECOGNITION (PSYCHOLOGY);

EID: 84929295239     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.015     Document Type: Article

References (68)

1. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339(6116):156-161.
2. Arif M., Chikuma T., Ahmed M.M., Yoshida S., Kato T. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions. Neurosci. Res. 2007, 57(2):248-258.
3. Bertaina-Anglade V., Enjuanes E., Morillon D., Drieu la Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J. Pharmacol. Toxicol. Methods 2006, 54(2):99-105.
4. Bezzi P., Vesce S., Panzarasa P., Volterra A. Astrocytes as active participants of glutamatergic function and regulators of its homeostasis. Adv. Exp. Med. Biol. 1999, 468:69-80.
5. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., Kanba S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):42-48.
6. 2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat. Front. Integr. Neurosci. 2014, 7:106.
7. Campos A.C., Moreira F.A., Gomes F.V., Del Bel E.A., Guimaraes F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367(1607):3364-3378.
8. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20years on. Neurosci. Biobehav. Rev. 2005, 29(8):1193-1205.
9. Catts V.S., Wong J., Fillman S.G., Fung S.J., Shannon Weickert C. Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation. Aust. N. Z. J. Psychiatry 2014, 48(8):722-734.
10. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin J.W. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
11. Diz-Chaves Y., Pernia O., Carrero P., Garcia-Segura L.M. Prenatal stress causes alterations in the morphology of microglia and the inflammatory response of the hippocampus of adult female mice. J. Neuroinflammation 2012, 9:71.
12. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50(11):1801-1807.
13. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav. Pharmacol. 2000, 11(3-4):223-233.
14. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14(1):1-21.
15. Esposito G., Scuderi C., Savani C., Steardo L., De Filippis D., Cottone P., Iuvone T., Cuomo V., Steardo L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 2007, 151:1272-1279.
16. Feresten A.H., Barakauskas V., Ypsilanti A., Barr A.M., Beasley C.L. Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr. Res. 2013, 150(1):252-257.
17. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 18(2):206-214.
18. Genius J., Benninghoff J., Reuter N., Braun I., Giegling I., Hartmann A., Moller H.J., Rujescu D. Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. Methods 2012, 56(4):519-527.
19. Gomes F.V., Issy A.C., Ferreira F.R., Viveros M.P., Del Bel E.A., Guimarães F.S. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int. J. Neuropsychopharmacol. 2015, 18(3):1-10.
20. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38(5):950-957.
21. Graeber M.B., Li W., Rodriguez M.L. Role of microglia in CNS inflammation. FEBS Lett. 2011, 585(23):3798-3805.
22. Guidali C., Vigano D., Petrosino S., Zamberletti E., Realini N., Binelli G., Rubino T., Di Marzo V., Parolaro D. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int. J. Neuropsychopharmacol. 2011, 14(1):17-28.
23. Hanson E., Healey K., Wolf D., Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr. Psychiatry Rep. 2010, 12(6):563-571.
24. Hoistad M., Heinsen H., Wicinski B., Schmitz C., Hof P.R. Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. Neuropathol. Appl. Neurobiol. 2013, 39(4):348-361.
25. Hoover W.B., Vertes R.P. Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat. Brain Struct. Funct. 2007, 212:149-179.
26. Hu X., Zhou H., Zhang D., Yang S., Qian L., Wu H.M., Chen P.S., Wilson B., Gao H.M., Lu R.B., Hong J.S. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol. 2012, 7(4):187-201.
27. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20(3):201-225.
28. Jentsch J.D., Taylor J.R., Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 1998, 19:105-113.
29. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
30. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., Cooper T.B., Macdougall L., Abi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62(9):985-994.
31. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71(5):520-527.
32. Lesh T.A., Niendam T.A., Minzenberg M.J., Carter C.S. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology 2011, 36(1):316-338.
33. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71(2):138-149.
34. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., Klosterkotter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94.
35. Lopez-Rodriguez A.B., Siopi E., Finn D.P., Marchand-Leroux C., Garcia-Segura L.M., Jafarian-Tehrani M., Viveros M.P. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb. Cortex 2015, 25(1):35-45.
36. Martim-Moreno A.M., Reigada D., Ramirez B.G., Mechoulam R., Innamorato N., Cuadrado A., Ceballos M.L. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 2011, 79:964-973.
37. Mecha M., Feliu A., Inigo P.M., Mestre L., Carrillo-Salinas F.J., Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol. Dis. 2013, 59:141-150.
38. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:115-121.
39. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 2007, 51(2-4):173-184.
40. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Moller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121(1-3):118-124.
41. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62(3):1574-1583.
42. Nakki R., Koistinaho J., Sharp F.R., Sagar S.M. Cerebellar toxicity of phencyclidine. J. Neurosci. 1995, 15(3 Pt 2):2097-2108.
43. Nakki R., Nickolenko J., Chang J., Sagar S.M., Sharp F.R. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp. Neurol. 1996, 137(2):234-241.
44. Oberheim N.A., Goldman S.A., Nedergaard M. Heterogeneity of astrocytic form and function. Methods Mol. Biol. 2012, 814:23-45.
45. Olney J.W., Labruyere J., Price M.T. Changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360-1362.
46. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2008, Academic Press, New York. 3rd ed.
47. Perez M., Benitez S.U., Cartarozzi L.P., Del Bel E., Guimaraes F.S., Oliveira A.L. Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats. Eur. J. Neurosci. 2013, 38(10):3424-3434.
48. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59(2):137-150.
49. Rajagopal L., Massey B.W., Huang M., Oyamada Y., Meltzer H.Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr. Pharm. Des. 2014, 20(31):5104-5114.
50. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57(2-3):127-138.
51. Ribeiro B.M., do Carmo M.R., Freire R.S., Rocha N.F., Borella V.C., de Menezes A.T., Monte A.S., Gomes P.X., de Sousa F.C., Vale M.L., de Lucena D.F., Gama C.S., Macedo D. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr. Res. 2013, 151(1-3):12-19.
52. Ribeiro-Santos R., Teixeira A.L., Salgado J.V. Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr. Neuropharmacol. 2014, 12(3):273-280.
53. Rothermundt M., Ahn J.N., Jorgens S. S100B in schizophrenia: an update. Gen. Physiol. Biophys. 2009, 28:F76-F81.
54. Rujescu D., Bender A., Keck M., Hartmann A.M., Ohl F., Raeder H., Giegling I., Genius J., McCarley R.W., Moller H.J., Grunze H. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 2006, 59(8):721-729.
55. Schiavon A.P., Soares L.M., Bonato J.M., Milani H., Guimaraes F.S., Weffort de Oliveira R.M. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox. Res. 2014, 26(4):307-316.
56. Schnieder T.P., Dwork A.J. Searching for neuropathology: gliosis in schizophrenia. Biol. Psychiatry 2011, 69(2):134-139.
57. Sidoryk-Wegrzynowicz M., Wegrzynowicz M., Lee E., Bowman A.B., Aschner M. Role of astrocytes in brain function and disease. Toxicol. Pathol. 2011, 39(1):115-123.
58. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119(1):7-35.
59. Tagliaferro P., Ramos A.J., Lopez E.M., Pecci Saavedra J., Brusco A. Neural and astroglial effects of a chronic parachlorophenylalanine-induced serotonin synthesis inhibition. Mol. Chem. Neuropathol. 1997, 32(1-3):195-211.
60. Tilleux S., Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 2007, 85:2059-2070.
61. 11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64(9):820-822.
62. Verwer R.W., Meijer R.J., Van Uum H.F., Witter M.P. Collateral projections from the rat hippocampal formation to the lateral and medial prefrontal cortex. Hippocampus 1997, 7:397-402.
63. Vigano D., Guidali C., Petrosino S., Realini N., Rubino T., Di Marzo V., Parolaro D. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J. Neuropsychopharmacol. 2009, 12(5):599-614.
64. Wake H., Moorhouse A.J., Nabekura J. Functions of microglia in the central nervous system-beyond the immune response. Neuron Glia Biol. 2011, 7(1):47-53.
65. Wozniak D.F., Brosnan-Watters G., Nardi A., McEwen M., Corso T.D., Olney J.W., Fix A.S. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res. 1996, 707:165-179.
66. Xia M., Abazyan S., Jouroukhin Y., Pletnikov M. Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophr. Res. 2015, (in press). 10.1016/j.schres.2014.10.044.
67. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56(10):485-486.
68. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20(5):683-686.